A fairly neutral result IMHO.. EBITDA loss for H2 is the most encouraging data point here, given markets are forward looking this does provide a foundation for a solid half this year.
The company is annoyingly tight-lipped when it comes to remarking on anything forward looking.
They have also confirmed that sales last month were materially higher YoY:
The company did mention they expect a material improvement in sales from the increased reimbursement:
With all of this, combined with improving gross margins, pathway to profitability seems set in stone however likely another CR to get us there
Ann: Full Year Financial Results, page-30
-
- There are more pages in this discussion • 185 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.010(6.06%) |
Mkt cap ! $35.50M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 15.5¢ | $58.82K | 372.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14029 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 83525 | 2 |
View Market Depth
| Last trade - 15.44pm 04/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |